Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Morris, M. [1 ]
Vogelzang, N. J. [2 ]
Sartor, O. [3 ]
Armour, A. [4 ]
Groaning, M. [5 ]
Messmann, R. [6 ]
Robarts, A. [7 ]
Petrylak, D. P. [8 ]
Tolcher, A. [9 ]
Gordon, M. S. [10 ]
Babiker, H. [11 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[2] Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA
[3] Tulane Univ, Oncol, New Orleans, LA 70118 USA
[4] Endocyte Inc, Med, Indianapolis, IN USA
[5] Endocyte, Clin, Indianapolis, IN USA
[6] Endocyte, Med Oncol, W Lafayette, IN USA
[7] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[8] Yale Univ, Sch Med, Med Oncol, New Haven, CT USA
[9] START, Med Oncol, San Antonio, TX USA
[10] HonorHlth Res Inst, Med Oncol, Scottsdale, AZ USA
[11] Univ Arizona, Ctr Comprehens Canc, Med Oncol, Tucson, AZ USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
793PD
引用
收藏
页数：1
相关论文
共 50 条
  • [11] The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Gupta, S.
    Yang, Q.
    Halabi, S.
    Tubbs, A.
    Gore, Y.
    George, D. J.
    Nanus, D. M.
    Antonarakis, E. S.
    Danila, D.
    Szmulewitz, R.
    Wenstrup, R. J.
    Armstrong, A. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1165 - S1166
  • [12] A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand
    Lee, Sung Chang
    Ma, Jennifer S. Y.
    Kim, Min Soo
    Laborda, Eduardo
    Choi, Sei-Hyun
    Hampton, Eric N.
    Yun, Hwayoung
    Nunez, Vanessa
    Muldong, Michelle T.
    Wu, Christina N.
    Ma, Wenxue
    Kulidjian, Anna A.
    Kane, Christopher J.
    Klyushnichenko, Vadim
    Woods, Ashley K.
    Joseph, Sean B.
    Petrassi, Mike
    Wisler, John
    Li, Jing
    Jamieson, Christina A. M.
    Schultz, Peter G.
    Kim, Chan Hyuk
    Young, Travis S.
    SCIENCE ADVANCES, 2021, 7 (33):
  • [13] Updated analysis of a phase II study using sorafenib (S) for metastatic castrate-resistant prostate cancer (mCRPC)
    Aragon-Ching, J. B.
    Jain, L.
    Draper, D.
    Gulley, J. L.
    Arlen, P. M.
    Wright, J. J.
    Jones, E.
    Chen, C. C.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [14] Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment
    Gernone, A.
    Pagliarulo, A.
    Calderoni, G.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [15] A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.
    Karzai, Fatima
    Madan, Ravi Amrit
    Owens, Helen
    Couvillon, Anna
    Hankin, Amy
    Williams, Monique
    Bilusic, Marijo
    Cordes, Lisa M.
    Trepel, Jane B.
    Killian, Keith
    Meltzer, Paul S.
    Gulley, James L.
    Lee, Jung-min
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [16] Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).
    Rami, Avina
    Ng, Thomas S. C.
    Rothmann, Emily
    Stoltenberg, Hailey
    Wolanski, Andrew
    Ritzer, Jolivette
    Choudhury, Atish Dipankar
    Gao, Xin
    Haberman, Veronica
    Kako, Bashar
    Kilbridge, Kerry L.
    Morgans, Alicia K.
    O'Shea, Aileen
    Taplin, Mary-Ellen
    Jacene, Heather
    Ravi, Praful
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 27 - 27
  • [17] Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics
    Kumar, Amit
    Mastren, Tara
    Wang, Bin
    Hsieh, Jer-Tsong
    Hao, Guiyang
    Sun, Xiankai
    BIOCONJUGATE CHEMISTRY, 2016, 27 (07) : 1681 - 1689
  • [18] A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Zurita, A.
    Shore, N. D.
    Kozloff, M. F.
    Ryan, C. W.
    Beer, T. M.
    Maneval, E. Chow
    Chen, I.
    Logothetis, C. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 287 - 287
  • [19] PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer
    Hope, Thomas A.
    Calais, Jeremie
    LANCET, 2021, 397 (10276): : 768 - 769
  • [20] Minimizing drug wastage (DW) and cost of cabazitaxel used to treat metastatic castrate-resistant prostate cancer (mCRPC).
    Jiang, Di Maria
    Fallah-Rad, Nazanin
    Lee, Roy
    Ng, Pamela
    Smith, Alan D.
    Hansen, Aaron Richard
    Joshua, Anthony M.
    Sridhar, Srikala S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345